> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/synergistic-combinations.md). # Synergistic Combinations ## Synergistic Combinations A general principle applies to all combination data here. Synergy in a cell line or animal model does **not** establish clinical safety or efficacy in combination. Drug interaction risks must be evaluated separately from biological synergy. ### Chemotherapy combinations #### Cisplatin This is the best-supported chemosensitisation combination in the apigenin literature. Apigenin enhances cisplatin cytotoxicity and apoptosis in a p53-dependent manner across lung, ovarian, colon, and osteosarcoma models. In cisplatin-resistant ovarian cancer cells (`SKOV3/DPP`), apigenin reversed resistance by downregulating `MCL-1`. In cisplatin-resistant colon xenograft models, apigenin inhibited tumour growth in vivo. #### Doxorubicin and sorafenib In hepatocellular carcinoma models, apigenin restores and enhances the antitumour effects of doxorubicin and sorafenib in both cell lines and mouse models. #### 5-fluorouracil, paclitaxel, and topoisomerase inhibitors Apigenin sensitises cancer cells to `5-FU` and paclitaxel across multiple cell-line studies. In leukaemia models, apigenin also sensitises cells to topoisomerase inhibitor agents, increasing apoptosis through a stronger DNA-damage response. Most of this evidence remains cell-line based unless otherwise stated. #### Gemcitabine Preclinical reports show enhanced gemcitabine activity in pancreatic cancer cell models. Evidence remains in vitro only. ### Immunotherapy combinations No direct human or animal trials have tested apigenin with checkpoint inhibitor drugs. The rationale rests on documented `PD-L1` suppression and `STAT3` inhibition in melanoma models. That makes the combination biologically plausible, but clinically untested. ### Targeted therapy combinations #### Imatinib A rat pharmacokinetic study found a bidirectional, time-dependent interaction. Short-term apigenin exposure inhibited imatinib metabolism and raised imatinib concentrations. Long-term co-administration appeared to accelerate metabolism and lower concentrations. This is not a synergy study. It is a genuine interaction warning for anyone using kinase inhibitors. #### Olaparib Apigenin modulates survival pathways and has been shown to restore olaparib sensitivity in vitro. This is early evidence, but relevant to PARP inhibitor resistance. #### BH3 mimetics Because apigenin suppresses `MCL-1`, which is a major resistance route to venetoclax and navitoclax, there is a strong mechanistic rationale for combining apigenin with BH3 mimetic strategies. This remains mechanistic and cell-line supported. No clinical combination trials exist. ### Natural-compound combinations #### Quercetin and apigenin Both compounds downregulate ABC transporter activity, including `P-glycoprotein`, `MRP2`, and `BCRP`. That may improve absorption and intracellular retention. Biologically, quercetin pressures `BCL-2/PI3K-AKT` signalling, while apigenin adds `MCL-1` pressure. That makes the pairing mechanistically layered rather than redundant. #### Fisetin, quercetin, and apigenin — senolytic pulse layer The three-compound [Senolytic Pulse Protocol](/myhealingcommunity-docs/senolytic-pulse-protocol.md) layers these compounds by survival-protein dependence: * **Fisetin:** pressures `BCL-xL`-dependent senescent cells * **Quercetin + bromelain:** pressures `BCL-2/PI3K-AKT`-dependent pathways while adding anti-inflammatory support * **Apigenin:** follows up on `MCL-1` and residual `BCL-2/BCL-xL` escape pathways in stressed and residual cells The rationale is mechanistically coherent across cell and animal data. Combination safety and optimal sequencing in humans have not been established in formal studies. ### References * Arango D, et al. [Apigenin enhances the cisplatin cytotoxic effect through p53-dependent apoptosis](https://pmc.ncbi.nlm.nih.gov/articles/PMC5351382/) * Qi Y, et al. [Apigenin induces apoptosis and reverses drug resistance in ovarian cancer by decreasing Mcl-1](https://e-century.us/files/ijcem/13/3/ijcem0104750.pdf) * Mahbub AA, et al. [The effect of apigenin and chemotherapy combination treatments on leukemia cells](https://pmc.ncbi.nlm.nih.gov/articles/PMC9132959/) * Huang S, et al. [Apigenin enhances sorafenib anti-tumour efficacy in hepatocellular carcinoma](https://pubmed.ncbi.nlm.nih.gov/38394865/) * Lan T, et al. [The Effect of Apigenin on Pharmacokinetics of Imatinib and Its Metabolite](https://pmc.ncbi.nlm.nih.gov/articles/PMC3863468/) * Lu Y, et al. [Apigenin modulates cell survival pathways and restores olaparib sensitivity](https://www.sciencedirect.com/science/article/pii/S1028455925003067) --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/synergistic-combinations.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.